Sex and gender differences in patients undergoing ablation of atrial arrhythmias by Carnlöf, Carina
From DEPARTMENT OF MEDICINE UNIT OF HEART AND 
LUNG DISEASES 
Karolinska Institute, Stockholm, Sweden 
SEX AND GENDER DIFFERENCES IN PATIENTS UNDERGOING ABLATION  
OF ATRIAL ARRHYTHMIAS 
Carina Carnlöf 
 
Stockholm 2018 
 
 All previously published papers were reproduced with permission from 
the publisher. 
The cover image was reproduced with permission from the collection of 
The State Hermitage Museum, St. Petersburg, Russia. 
Published by Karolinska Institute. 
Printed by Eprint AB 
© Carina Carnlöf, 2018 
ISBN 978-91-7831-133-0 
 
 
SEX AND GENDER DIFFERENCES IN PATIENTS UNDERGOING ABLATION  
OF ATRIAL ARRHYTMIAS 
 
 
THESIS FOR DOCTORAL DEGREE (PhD) 
By 
Carina Carnlöf 
Principal Supervisor: 
Med Dr Per Insulander  
Karolinska Institute 
Department of Medicine, Huddinge 
Division of Heart and Lung Diseases 
 
Co-supervisor(s): 
Med Dr Marie Iwarzon  
Karolinska Institute 
Department of Neurobiology, Care of                 
Sciences and Society 
Division of Nursing 
 
Docent Fredrik Gadler 
Karolinska Institute 
Department of  Medicine, Solna 
Division of Heart and Lung Diseases 
Opponent: 
Professor Lennart Bergfeldt 
University of Gothenburg 
Department of Medicine 
Division of Molecular and Clinical Medicine 
 
Examination Board: 
Professor Tomas Jernberg 
Karolinska Institute 
Department of Medicine 
Division of Clinical Science 
 
Professor Karin Schenck-Gustafsson 
Karolinska Institute 
Department of Medicine, Solna 
Division of Heart and Lung diseases 
 
Docent Kerstin Ulin 
University of Gothenburg 
Department of Sahlgrenska Academia 
Division of Health and Care Science 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TO MY BELOVED FAMILY,  
AND IN LOVING MEMORY OF 
INGRID AND WALDEMAR  
KARLENSTEDT 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Det är först då fågeln kastar sig ut i den fria rymden som han känner att han har vingar. 
– C. Wagner 
 
  
ABSTRACT 
Background: Women and men differ in the prevalence of arrhythmias. Furthermore, there are sex and 
gender differences in referral for ablation, symptom severity, health-related quality of life (HRQOL), 
functional impairment and response to treatment, risk factors, and outcomes.  
Aim: This thesis studies sex and gender differences in referral, treatment, outcome, symptom, 
HRQOL, and functional impairment in patients undergoing cardiac ablation of atrial fibrillation and 
paroxysmal supraventricular tachycardia (PSVT).   
Method: The thesis is based on four studies. Study I and II are observational prospective studies based 
on questionnaires before and six months after ablation. Study I include 214 (109 women) patients 
referred for PSVT ablation and Study II includes 242 (121 women) patients with atrial fibrillation 
referred for pulmonary vein isolation (PVI). The following questionnaires were used: Symptom 
Checklist: Frequency and Severity, Short Form 36, and Sickness Impact profile. Referral patterns and 
socio-economic data and symptom duration were evaluated with a separate questionnaire. In Study III, 
700 patients (359 women) who had undergone AV-nodal junction (AVJ) ablation between 1990 and 
2010 were retrospectively studied. Data were sampled from medical records, the Swedish ICD and 
Pacemaker Registry, and from the National Patient Registry kept by the National Board of Health and 
Welfare. Study IV was conducted with 80 (40 women) patients randomized either to an active or a 
standard pain treatment during PVI using cry-or radiofrequency energy. Evaluation of the two 
treatments strategies was assessed with a questionnaire based on the Pain-O-Meter.  
Results: In Study I, although women had more PSVT symptoms, they were referred in mean six years 
later than the men. In addition, women more often reported they were not believed when describing 
their arrhythmia symptoms and were consequently more often diagnosed with stress and anxiety. In 
Study II, no such sex difference was found, but women were more symptomatic, assessed a lower 
HRQOL and a greater functional impairment than the men. Furthermore, women more often received 
drug treatment and were less often than men referred for cardioversion before ablation. In Study III, 
heart failure was present in more men than women before the AVJ ablation. When indication 
presented before ablation, women less often than men received implantable cardioverter-defibrillator 
(ICD) or cardiac resynchronization therapy (CRT). There were no differences between the sexes 
regarding primary cause of death, and cardiovascular mortality was the most common cause of death. 
The main parameter influencing survival was age at the time of AVJ ablation. In Study IV, over 90% 
of the patients experienced pain during the PVI. Premedication and regular administration of analgesic 
resulted in less pain and fewer drug administration occasions. Women experienced more pain than 
men regardless of energy type, cryo - or radiofrequency energy.  
Conclusion: All four studies showed that there were sex and gender difference in either referral, 
morbidity, symptom, HRQOL, functional impairment or response to treatment. Women with PSVT 
and atrial fibrillation were treated more conservatively than men. Women with PSVT were referred 
for curative ablation later than men despite having more symptoms. Symptoms due to PSVT in 
women were more often incorrectly diagnosed as panic attacks, stress, anxiety, or depression. 
Furthermore, women with atrial fibrillation were more symptomatic, assessed a lower HRQOL and a 
greater functional impairment but despite that, were more seldom referred for cardioversion before 
PVI.  Women less often received CRT or ICD implantation even when indication was present before 
AVJ ablation. We found no sex differences regarding survival or primary cause of death after AVJ 
ablation. The main factor influencing survival was age at the time of ablation. Women experienced 
more pain than men during PVI, but an active regular supply of analgesic and sedative drugs reduced 
pain and discomfort during PVI in both sexes. 
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1 INTRODUCTION 
1.1 BRIEF HISTORY 
The beating heart and irregular heartbeats have impressed and fascinated people for more 
than two thousand years. In the fifth century before Christ, the Chinese physician Pien TsÍo 
made a significant breakthrough laying the foundation of the pulse theory in the identification 
and treatment of cardiac arrhythmias (1). In this theory, the pulse was studied as a reflection 
of cardiac activity and the pulse beat as a diagnostic and prognostic criterion of pathology. 
His theory compared the human body to a stringed instrument where a skilled observer could 
detect both harmony and dissonance (1). This was one of the first pulse theories, but many 
more studies of the pulse have been described through the history, starting in ancient Egypt, 
Greece, and Arabia. Arrhythmia disturbance and pulse analysis have also been described in 
music and paintings. In the early 1800s, Ludwig van Beethoven set his own cardiac rhythm 
disturbance to music in the piano sonata opus 8, “Les adieux”. The Dutch artist J. S. Steen 
(1626-1679) made several paintings in oil showing physicians analysing the pulse in sick 
women (1).   
 The Doctor's Visit" by Jan Steen 
A first attempt to obtain an electrocardiogram (ECG) from the body surface was made by 
A.D. Waller (1856-1922) as early as 1887 (2). He published his work in The Journal of 
Physiology but the clinical significance of his discovery of the ECG curve was not recognized 
at the time. Twenty years later, W. Einthoven (1860- 1927) identified and named four waves 
(P, Q, R, S) in each ECG when he experimented with the recently invented string 
galvanometer. The discovery with waves in the ECG was crucial for future studies of cardiac 
disturbances. In 1924, W. Einthoven won the Nobel Prize in Medicine for his work with the 
string galvanometer (3). 
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Willhelm His (1863-1934), living and working in Germany, studied the heart and metabolic 
conditions. In animal experiments, he found that if the atrium was separated by septum, a 
dissociated heart rhythm would occur. In a work from 1893, he described the structure that 
today carries his name, His bunt (1). His bundle constitutes the extension of the AV node that 
divides into the right and left branches in the ventricle (4).  
 
1.1.1 Treatment breakthroughs 
In 1981, Scheinman et al. performed the first intentional atrio-ventricular junction (AVJ) 
ablation on a human to control refractory supraventricular arrhythmias (accidental AV block 
had been reported earlier) (5). The technique used was a portable defibrillator with standard 
electrodes that delivered a high-energy direct current chock (300-500 J) that created a 
complete AV block. In the late 1980s, the use of direct current shock was replaced with safer 
radiofrequency energy (6, 7). In Sweden, ablations of arrhythmias with radiofrequency (RF) 
energy have been a routine treatment since the early of 1990s. 
On 8 October 1958 at Karolinska University Hospital, Åke Senning implanted the first 
pacemaker in a patient with total atrioventricular block (8). In 1980, Mieczyslaw Mirowsky 
implanted the first automatic cardioverter defibrillator (ICD) in a human, which was placed in 
the abdomen due to its size (9). In 1993, the first ICD placed in pectoralis was introduced (9).   
 
1.2 DEFINITIONS 
1.2.1 Gender and sex 
The terms gender and sex are often used equivalently, but there is an important distinction. 
The World Health Organization (WHO) define the terms as follows:  
“Sex” refers to the biological and physiological characteristics that define men 
and women and “Gender” refers to the socially constructed roles, behaviours, 
activities, and attributes that a given society considers appropriate for men and 
women. (http://www.who.int/gender/whatisgender/en/) 
WHO further states that “male” and “female” are sex categories, and “masculine” and 
“feminine” are gender categories:  
 3 
 
Women menstruate while men do not, men have testicles while women do not, 
women have developed breasts that are usually capable of lactating, while men 
do not, and men generally have more massive bones than women. 
(http://www.who.int/gender/whatisgender/en/) 
In addition, the sex categories cannot be changed, whereas gender characteristics are 
changeable:  
In the United States (and most other countries), women earn significantly less 
money than men for similar work. In Viet Nam, many more men than women 
smoke, as female smoking has not traditionally been considered appropriate. 
(http://www.who.int/gender/whatisgender/en/) 
An example of a changed gender characteristic recently made news headlines. Before 2018, 
in Saudi Arabia women were not allowed to drive cars and this restriction was used as an 
example of gender characteristics by the WHO: “In Saudi Arabia men can drive cars while 
women cannot” (http://www.who.int/gender/whatisgender/en/). However, as of 2018, women 
are now allowed to drive cars in Saudi Arabia (10).  
According to the Sex and Gender Equity in Research (SAGER) guidelines, developed by the 
European Association of Science Editors, the term sex and gender should be used carefully to 
avoid confusion (11). The term sex (male or female) should be used only as a biological 
classification, and the term gender (masculine and feminine) should be used only as a social 
and cultural characteristic (11). In this thesis we have strived to consistently use the 
terminology recommended by SAGER. 
 
1.2.2 Quality of life and Health-related quality of life  
Quality of life (QOL) as a concept has been used in a variety of areas for a long time. The 
concept can be traced back to the Greek philosophers. According to Rustoen (1993), the 
concept of QOL derives from a speech given in 1964 by the US President Lyndon B Johnson: 
“The criterion of progress cannot be sought in the banking book but in the                              
quality of the life we live” (12). 
Quality of life is an ambiguous term, so it is difficult to define. The concept often includes 
satisfaction with everyday life, both past and present. An individual’s QOL can be affected 
by economic conditions, physical environment, education, employment, cultural 
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opportunities, and psychological and physical well-being. The World Health Organization 
(WHO) defines QOL as follows:  
An individual’s perception of their position in life in the context of the culture 
and value systems in which they live and in relation to their goals, 
expectations, standards and concerns. It is a broad-ranging concept, affected 
in a complex way by the person’s physical health, psychological state, 
personal belief and social relationships to salient features of their  
environment (13).  
http://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/.  
Health status is related to the QOL concept in science, but in the clinical care it has been 
limited to Health-Related Quality of Life (HRQOL). HRQOL refers mainly to function and 
well-being related to health, illness, and treatment. The concept includes both positive and 
negative experiences of a medical condition. The focus is on the individual in a health care 
context and thus contributes to the individual aspect considered in the care and treatment. 
Specifically, HRQOL relates to a patient’s ability to adapt to her illness, resources, and needs 
(13).  
 
1.2.3 Symptoms 
The definition of “symptom” derives from the Greek word “symptoma”, which means 
“anything that has befallen one”. In an international dictionary, the word symptom is defined 
as “the subjective evidence of disease or physical disturbance observed by a patient” (14). 
Symptoms are only known by the person experiencing the symptoms. Fever or high blood 
pressure can be measured and observed by others and are “signs” of disease.  The disease 
itself, can produce symptoms. Symptoms can also be produced by side effects or toxicities of 
a treatment or arise from comorbid medical conditions or acute injuries. Symptoms often 
occur in clusters and have been shown additive in their impact on for example cancer  
patients (15). 
A routine assessment of the patient’s self-reported symptom burden and HRQOL with 
validated instruments can be beneficial for physicians when deciding on a treatment and can 
be an indicator of the patient’s recovery and treatment outcome. It is important that patients 
assess their symptoms themselves to avoid the risk of underestimation. Earlier studies have 
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shown that healthcare professionals tend to underestimate symptoms such as pain and rate the 
patient’s symptom lower than the patient herself (16-18). 
A patient’s own assessment reflects the patient’s daily health status. In oncology practice, 
self-assessment has been shown to be a beneficial strategy, improving the clinician’s ability 
to predict unfavourable clinical events. Both the clinician’s and the patient’s perspectives are 
central, complementary, and provide meaningful information (19, 20). 
 
1.3 ARRHYTHMIA 
There are several differences between men and women in the presentation of electro-
physiology and cardiac arrhythmias (Table I) (21, 22). One of the first to describe the 
differences in the heart rhythm between men and women was H. Bazett. In 1920, Bazett 
found that women had higher heart rate at rest and longer QT interval than men (23). These 
findings have been confirmed in later reports (24, 25). In a large population-based study (over 
5 000 participants), women’s average resting heart rate was 3-5 beats higher than men’s (24). 
Women also have shorter QRS duration, sinus-node recovery time, and AV nodal 
refractoriness, and faster conduction through the AV node (26, 27). Stress produces a more 
pronounced effect on the AV node and on the sinus node in women, whereas men react with 
a more pronounced effect on ventricular electrophysiologic properties. Certain gender 
differences in cardiac electrophysiologic properties seem to be intrinsic. After autonomic 
tone inhibition, women have higher heart rate and shorter AV nodal refractoriness but longer 
QT and JT intervals and longer effective refractory period in the right ventricle (28).  
This difference in AV nodal refractoriness may partly explain why women often have faster 
heart rate during atrial fibrillation and supraventricular tachycardia. Factors such as 
differences in body habitus and autonomic nervous system are also important (29). Moreover, 
female hormones are known to affect the calcium and potassium channel, which may prolong 
the QT interval and therefore increase the risk of arrhythmic events (22). 
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Table I. Examples of sex differences in electrophysiological properties and arrhythmias 
Electrophysiological properties Male predominance Female Predominance 
Heart rate  3-5 beats higher heart rate at rest in women 
Sinus node recovery time  Shorter in women 
ORS-complex  Narrower and lower voltage in women 
Q-T interval  10 -20 ms longer in women (longer during 
menstruation period) 
Arrhythmia type   
Bradyarrhythmia High-Degree AV-block Sinus node disease 
 Carotid sinus syndrome  
Supraventricular tachyarrhythmias  Atrial fibrillation AV nodal reentrant tachycardia 
 AV reentrant tachycardia   
Ventricular tachyarrhythmias Ventricular tachycardia Long QT syndrome 
 Brugada syndrome Torsade’s de pointes 
 Sudden cardiac death  
   
 
1.3.1 Atrial fibrillation 
Atrial fibrillation (AF) is the most common supraventricular tachyarrhythmia. In a 2006 
report from Rotterdam, the estimated lifetime risk to develop AF was one in four among 
middle-aged adults in Europe (30). Risk factors for developing AF are primarily age, 
hypertension, heart failure (HF), and valve disease (31-33). AF is one of the major causes 
of HF, stroke, dementia, cardiovascular morbidity and sudden cardiac death, and high 
health costs (34-36). The recommended treatment strategies from the European Society of 
Cardiology (ESC) 2016 regarding AF includes rate and rhythm control, stroke prophylaxis, 
and life style changes are shown in Figure I (34).  
 
1.3.2 Rhythm control of atrial fibrillation 
In patients with AF who experience severe symptoms and low HRQOL despite a good 
ventricular rate control, restoring sinus rhythm may be necessary (37). As a first-line 
therapy, anti-arrhythmic drug (AAD) therapy is generally recommended (38). In patients who 
continue to have recurrent episodes of atrial fibrillation despite medical therapy or have 
complications associated with AAD, PVI has shown to substantially decrease symptoms and 
improve the HRQOL (39, 40). PVI performed in experienced centres has shown to be more 
effective than AAD therapy (41-44). In younger patients with paroxysmal AF, PVI as a first 
line treatment has shown to be cost-effective (45). 
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1.3.3 Rate control of atrial fibrillation 
If medication fails, pacemaker implantation and AVJ ablation has shown to control rate and 
symptoms. The procedure is uncomplicated with a low long-term mortality risk and 
complication rate, but the patients will be pacemaker-dependent for the rest of their lives 
(46). According to current guidelines, AVJ ablation should be considered in patients 
nonresponsive or intolerant to rate and rhythm control (34).  
To avoid negative effects and dyssynchrony, a pacemaker system with a left ventricular 
electrode to achieve biventricular (BiV) pacing may be implanted (47). The choice of pacing 
therapy depends on the ejection fraction (EF) and the individual patient characteristics (48, 
49). Cardiac resynchronization therapy (CRT) reduces mortality and hospitalization and 
improves cardiac function in patients with severely depressed EF (<35%) and QRS duration 
(≥ 120 ms) (50). 
In patients with HF who receive CRT, it is important that the percentage of BiV pacing is 
>90% and AVJ ablation may be needed to achieve full effect of CRT in HF patients with 
AF and rapid conduction (51).  
In selected patients, the ejection fraction has shown to improve after the AVJ ablation (52-
54). On the contrary, a negative effect of permanent pacemaker stimulation is 
dyssynchronous movement patterns of the ventricles. This might lead to an impaired EF 
and development of HF, especially in patients with previous impaired cardiac function (55). 
In this group of patients, an increased mortality after the AVJ ablation has been found (56). 
Ozcan et al. found several independent predictors for sudden death after AVJ ablation: 
diabetes mellitus, New York Heart association functional class (≥ II), earlier ablation, 
ventricular arrhythmia, mitral or aortic stenosis, aortic regurgitation, and chronic obstructive 
pulmonary disease (57).  
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Figure I. Adapted and modified from 2016 European Society of Cardiology  of AF management strategies (34) 
                                                               Treatment                              Desired outcome                                               Patient benefit 
 
 
 
 
 
 
 
 
 
 
 
1.3.4 Atrial fibrillation and sex and gender differences 
There are sex and gender differences in prevalence, complications, and treatment of AF. The 
prevalence for AF is higher in men than women but women have a similar or higher 
incidence of stroke and death due to AF (32, 58). Moreover, women with AF are less likely to 
receive specialist care, rhythm control therapy, cardioversion, or catheter ablation than men 
despite current guidelines (34, 59). The reasons for this discrepancy between men and women 
are unknown. The outcomes of catheter ablation seem to be equally effective in women and 
men, but overall complications are significantly higher among women (60, 61). In a large 
register study (nearly 90 000 patients), women were 1,5 times more likely to have major 
adverse events such as vascular access complications, pericardiocentesis, and post 
procedure bleeding requiring transfusion (61). Obesity, diabetes, hypertension, renal 
failure, chronic pulmonary disease, cerebrovascular accident, and older age were also more 
common in women than men (61).  
 
In a registry study from Germany, data from 9 576 patients (39% women) with AF were 
studied, showed that women experienced more severe symptoms than men during AF. The 
women had higher heart rate, more frequent palpitations, severer shortness of breath, chest 
pain, and dizziness (62). Only 16% of the women were completely free of symptoms before 
pharmacological treatment compared with 27% of the men. This finding supports previous 
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reports, which were less comprehensive (39, 63). These studies also show that AF patients 
estimated their HRQOL lower than the normal population before pharmacological treatment 
was initiated (39, 63). In the 2005 RACE study, Rienstra et al. reported a lower HRQOL and 
more symptoms due to AF in women than in men (64). In 2000, Paquette et al. found that the 
women with AF had worse physical functioning than men independent of other concomitant 
heart diseases and age. In contrast, AF had a less negative effect on the mental and general 
well-being in women compared to men (65). 
 
1.3.5 Paroxysmal supraventricular tachycardia 
Atrio-ventricular nodal reentrant tachycardia (AVNRT) and atrio-ventricular reentrant 
tachycardia (AVRT) constitute about 90% of all regular paroxysmal supraventricular 
tachycardias (PSVT). PSVT episodes are characterized by a sudden start and stop. The heart 
rate is typically between 140-250 beats per minute (66). Symptoms due to the high rate are 
therefore often similar to the symptoms of AF: palpitations, shortness of breath, fatigue, 
dizziness, syncope, and angina and in certain cases myocardial infarction (67, 68). The 
difference is that episodes of AVNRT and AVRT very seldom are asymptomatic because no 
rate modifying effect is possible in the AV node. Ablation has been the treatment of choice in 
these arrhythmias since the late 1990s and has a high success rate and a very low 
complication rate (66, 69). 
 
1.3.6 Paroxysmal supraventricular tachycardia – sex and gender differences  
Women have a higher risk for AVNRT than men (Table I) (66). On the contrary, AVRT is 
more common in men. Previous studies show that women are referred for ablation several 
years later than men despite more severe symptoms (70, 71). It is unknown whether the 
reason for this discrepancy is caused by a patient´s or a doctor´s delay. Because symptoms 
during episodes of PSVT often resemble what is experienced in panic disorder and other 
psychiatric conditions, PSVT might be misinterpreted as anxiety attacks or panic disorder. 
Moreover, women seem to be at a higher risk than men of being incorrectly diagnosed and 
incorrectly treated (68, 72, 73). 
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1.3.7 Pain and sex differences 
Men and women differ in response to pain. Earlier research has demonstrated greater pain 
prevalence among women compared to men (74). Large-scale epidemiological studies across 
multiple geographic regions found that pain is reported more frequently by women than by 
men (74). There are several physiological systems that may affect analgesics and pain (e.g., 
hormones, body fat, liver metabolism, and immune responses) (75-78). There also seems to 
be an age component as many common pain conditions increase during the puberty, 
especially in women (79). Moreover, psychosocial and sociocultural mechanisms affect how 
pain is handled (80). Robinson et al. reported that both women and men believed that men are 
less willing to report pain than woman. This gender role expectation may contribute to sex 
differences in experimental pain (81). 
 
1.3.8 Pain and cardiac ablation 
During cardiac ablation, effective analgesic and sedation is necessary to carry out the 
procedure safely and pain free. (82). Catheter cryo balloon ablation compared to 
radiofrequency (RF) seems to be better tolerated and less painful (83). The most common 
way to reduce discomfort and anxiety during ablation is to use conscious intravenous sedation 
and analgesia (84).  Usually, this is administered by trained nurses under the supervision of a 
physician at the electrophysiology laboratory (84). This approach maintains spontaneous 
respiration so anaesthesia services are not needed (84).  
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2 OVERALL AIM 
The overall aim of this thesis was to study sex and gender differences in referral, treatment, 
outcome, symptom, HRQOL, and functional impairment in patients undergoing cardiac 
ablation of atrial fibrillation and PSVT. 
 
2.1 SPECIFIC AIM 
Study I. With a gender perspective, Study I specifically evaluates morbidity, HRQOL, 
symptoms, and functional impairment in patients with PSVT before and six months after ablation 
and the patients’ experiences and perspectives of their ablation referral. 
 
Study II. With a gender perspective, Study II evaluates morbidity, HRQOL, symptoms, 
and functional impairment in patients with AF before and six months after PVI and the 
patients’ experiences and perspectives of their ablation referral. 
 
Study III. Study III evaluates possible sex bias in patients with AF receiving AVJ 
ablation regarding indication and choice of pacing system and compares differences 
between the sexes with respect to complications, morbidity, and long-term mortality. 
 
Study IV. Study IV evaluates whether a more active supply of analgesic and sedative 
drugs reduce pain and discomfort during PVI. Furthermore, this study evaluates sex 
differences in pain perception and compares standard radiofrequency with cryo energy 
ablation. 
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3 PATIENTS AND METHODS 
3.1 PATIENTS AND SELECTIONS 
The participants in the studies were all referred for cardiac ablations to the cardiology 
department at Karolinska University Hospital between 1990 and 2015. Patients were 
excluded if they could not read, write, or understand the Swedish language, had cognitive 
disturbances, or did not return a signed informed consent.  
 
3.2 OVERVIEW OF THE STUDY DESIGN 
 
Study  I II III IV 
Number of patients 214 (109 women) 242 (121 women) 700 (359 women) 80 (40 women) 
Design Prospective 
observational study 
Prospective 
observational study 
Retrospective 
longitudinal registry 
study 
Randomized 
interventional                   
study  
Including period February 2013 -     
May 2015 
February 2013 -
January 2016 
January 1990 -     
December 2010 
April 2007   January 
2011 
Data collection 
method 
Patients file, SF-36*                                            
SIP**, SCL***, 
Questionnaire 
regarding the referral 
process                                   
Patients file, SF-36*                                            
SIP**, SCL***, 
Questionnaire 
regarding the 
referral process                                   
Patients file, local 
ablation registry, 
Swedish ICD and 
Pacemaker Registry, 
Patient Registry kept 
by the National 
Board of Health and 
Welfare 
Patients file, 
Questionnaire 
regarding experienced 
pain, Pain-O-Meter  
Data analyses Descriptive and 
statistical analyses 
Descriptive and 
statistical analyses 
Descriptive and 
statistical analyses 
Descriptive and 
statistical analyses 
*Medical Short Form 36, **Sickness Impact Profile, ***Symptom Checklist: Frequency and Severity Scale 
 
3.3 QUESTIONNAIRES 
Two types of questionnaires were used: general and symptom-specific questionnaires. 
General questionnaires identify and compare patient groups and symptom-specific 
questionnaires are used for individual patients and special conditions (85). The purpose 
and/or research question determines the choice of questionnaires: What it is you want to 
measure and why? If a questionnaire is too general, it may exclude significant areas.  
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3.3.1 Medical Short Form 36  
For the last few decades, the most common general questionnaire used for patients with 
arrhythmias has been the Medical Short Form 36 (SF-36). This questionnaire has been 
translated into Swedish and adapted and evaluated at the School of Care Sciences, 
Sahlgrenska University Hospital in Gothenburg. This was done in collaboration with the 
International Quality of Life Assessment as a project to match the original U.S. Medical 
Outcomes Study Short-Form Health. SF-36 is based on the WHO’s health concept defined 
in 1948 and is widely used in public health and epidemiological research (86, 87). Unlike 
the symptom-specific instruments, SF-36 is less sensitive to small variations and changes. 
SF-36 measures eight health domains with five functional scales and three well-being 
scales. The five functional scales measure the degree of dysfunction and the three well-
being scales cover the whole spectrum from negative to positive health. In addition to these 
eight subscales, there are also two summary scales – Physical health (PCS) and Mental 
health (MCS) – calculated from the eight scales weighted into the two measurements (Table 
II) (88).  
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Table II. SF-36 scales                          Definitions of Lowest and Highest Scores 
Scale 
 
Items  
 
Lowest possible (floor) 
 
Highest possible (ceiling) 
 
Physical Health /functional 
scales       
Physical Functioning (PF) 10 Limited a lot in performing all physical 
activities including bathing or dressing due 
to health 
Performs all types of physical activities 
including the most vigorous  
Role- Physical (RP) 4 Problems with work or other daily 
activities as a result of physical health 
No problems with work or other daily 
activities as a result of the physical health 
Role -Emotional (RE) 3 Problems with work or other daily 
activities as a result of emotional problems 
No problems with work or other daily 
activities as a result of emotional problems 
Social-Functioning (SF) 2 Extreme and frequent interference with 
normal social activities due to physical or 
emotional problems 
Performs normal social activities without 
interference due to physical or emotional 
problems 
Bodily Pain (BP) 2 Very severe and extremely limiting pain No pain or limitations due to pain 
Mental Health/well-being scales       
Mental Health (ME) 5 Feelings of nervousness and depression all 
the time 
Feels peaceful, happy, and calm all the 
time  
General Health (GH) 5 Evaluates personal health as poor and 
believes it is likely to get worse 
Evaluates personal health as excellent 
Vitality (VT) 4 Feels tired and worn out all the time Feels full of pep and energy all the time 
 
Modified from the Swedish Manual and Interpretation Guide (86).  
 
3.3.2 Symptom checklist: Frequency and Severity scale 
Symptom Checklist: Frequency and Severity Scale (SCL) version 3 was developed by Bubien 
and Jenkins in 1996 to measure symptoms in patients with cardiac arrhythmias (39). SCL is 
presently one of the most frequently used symptom-specific instruments for arrhythmia 
patients (85, 89). In patients with dual pacemakers, the SCL has been used to evaluate the 
mode switch function. In addition, SCL has been used to measure the outcome after isthmus 
ablation, ICD, and concomitant AF, AF after AVJ ablation, as well as in long-term follow-up 
in patients who have undergone ablation of supraventricular tachycardia (89-94).  
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SCL has not previously been translated into Swedish, validated, or reliability tested. 
Nevertheless, SCL together with the Swedish SF-36 have been used for comparison when 
developing new symptom specific arrhythmia instruments in Sweden (95-97). Therefore, 
simultaneously with the studies in this thesis, the SCL was translated into Swedish and 
psychometric properties were evaluated with exploratory factor analyses for use in patients 
with AF, atrial flutter, and paroxysmal tachycardia (Submitted for publication). 
3.3.2.1 Translation procedure, face, and content validity of the SCL 
Translation procedure followed the steps recommended by the WHO (98). The steps included 
forward translation of the SCL from English to Swedish performed by a person familiar with 
English-speaking language, face and content validity assessment by expert panel, and face 
validity in sample with a pre-test on a target population. The Swedish SCL was tested by six 
patients referred for cardioversion and by six patients referred for PSVT ablation. The 
patients were interviewed with the “think aloud method” and were asked to evaluate the 
intelligibility of the questions (99). The forward-backward translations using the WHO’s 
recommendations yielded no differences in the descriptions of the items in the SCL. 
Thereafter, the author, Louise Jenkins, gave permission to use the Swedish version of the 
SCL. According to the authors of SCL, the reliability of the two scales (frequency and 
severity) of the SCLs should be calculated using Cronbach’s alpha to estimate the internal 
consistency at each data collection point. Values obtained were for both Study I and II: > .87 
for the frequency and >.89 for the severity scale.   
  
3.3.3 Sickness Impact Profile 
Sickness Impact Profile (SIP) measures the self-rated functional capacity to perform daily 
activities in chronic and acute medical conditions. The instrument was developed by Bergner 
et al. in the United States and was translated and validated for Swedish conditions by Sullivan 
et al. (100, 101). The instrument includes 136 items that form 12 scales. Points can be shown 
as total index (i.e., all 12 categories merged) for the physical and psychosocial index along 
with the remaining five categories or for the twelve-part categories separately. In Study I and 
II we chose to use the following ten scales: ambulation, mobility, emotional behavior, 
communication, work, sleep and rest, social interaction, alertness behavior, home 
management, recreation, and pastime (Table III). The excluded items were body care and 
food intake. We judged these questions unfit in our specific study population, and the 
exclusion of the items did not affect the validity of the scale. Lower values indicate less 
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functional impairment. SIP has previously been used in studies for patients with arrhythmia 
(102, 103). 
 
Table III. Dimensions and categories and number of claims at each category in Sickness Impact Profile  
Dimension/Category 
 
 
Number of claims 
 
Physical function  
             Ambulation 12 
             Body Care and Movement* 23 
             Mobility 10 
 
Psychosocial function  
            Social Interaction 20 
            Alertness behaviour 10 
            Emotional behaviour 9 
            Communication 9 
 
Independent categories  
           Sleep and Rest  7 
           Eating* 9 
           Work 9 
           Home management 10 
           Recreation and Pastimes 8 
 
Total 136 
• Excluded dimensions in study I and II 
 
 
3.3.4 Pain-O-Meter 
In Study IV, the pain was assessed during the ablation with the Pain-O-Meter (POM). The 
instrument is well-validated, based on the visual analogue scale (VAS) and the McGill Pain 
questionnaire (12). Conventionally, the POM is a hard-plastic tool with the VAS scale that 
has a list of sensory and affective words that describe the experience of pain and a picture of a 
body. In Study IV, we turned the POM instrument details into a picture of a body where 
patients could mark the location of their pain. We also used the POM word description of the 
overall dimension (appendix 4).     
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3.4 STUDY I AND II 
Study I and II had the same design – descriptive observational studies based on 
questionnaires that included patients who were refereed for their first cardiac ablation due to 
PSVT in Study I and AF in Study II. Before the start of the studies, six patients during 
cardiac ablation-related hospitalization were interviewed using a half-structured questionnaire 
regarding their experience with their referral for the arrhythmia (appendix 1). These patients 
were not included in the latter study. The interviews were taped and transcribed verbatim. 
After the transcribed interviews were analysed, the following themes were found: anxiety and 
worries not believed or being treated impolitely when seeking health care. A questionnaire 
was constructed including the two themes as well as questions regarding referral patterns, 
socioeconomic data, and symptom duration (appendix 2). Arrhythmia symptoms were 
evaluated with the SCL, the HRQOL with SF-36, and the functional impairment with SIP at 
baseline and six months after ablation. All questionnaires were sent home to the patient 
together with an informed consent and information and about the study less than 30 days 
prior to the ablation. 
 
3.5 STUDY III 
In Study III, all included participants (700) had undergone AVJ ablation between January 
1990 and December 2010 and the data were collected from the institution´s ablation register 
at the Karolinska University Hospital. Information about the pacemaker system and 
complications due to the implant was retrieved from the Swedish ICD and Pacemaker 
Registry. Patient files were used for clinical data, indication, and concomitant disease. Data 
regarding mortality, primary cause of death, and out clinic visits due to HF, stroke, or 
ventricular tachycardia were obtained from National Patient Registry kept by the National 
Board of Health and Welfare. The diagnosis codes shifted during the follow-up periods. For 
data between 1990 and 1996, the ninth revision of the International Classification of Diseases 
(ICD9) coding for diagnosis was used; for data between 1997 and 2012, the tenth revision of 
the ICD (ICD10) coding was used (Table IV). 
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Table IV. International Classification of Diseases  
Diagnose codes ICD-9 (1990–1996) ICD-10 (1997–2012) 
Stroke 430–438 I60-I69 
Atrial fibrillation 427D I48 
Heart failure 428 I50-0.09 
Ventricular tachycardia 427B I47:0–9 
Ventricular fibrillation 427E, 427D I49.0 
Cardiac arrest  I46.0 427F 
For data between 1990 and 1996, the ninth revision of the International Classification of Diseases (ICD9) was used. For data 
between 1997 and 2012, the tenth revision of the International Classification of Diseases (ICD10) was used for coding the 
causes of death.  
 
3.6 STUDY IV 
Study IV included 80 patients – 40 men with mean age 56 (range 23-72) and 40 women with 
mean age 63 (range 50-76) – scheduled to undergo PVI. The participants were randomized 
into two pharmacological treatments. They were randomized in groups with an equal number 
of men and women. One group (A) received a more active analgesic strategy and the control 
group (C) was offered standard treatment and received analgesic and sedatives on request. 
The participants in group A were given midazolam 30 min before the procedure; thereafter, 
they received medication according to a predetermined protocol (appendix 3). The choice of 
RF energy versus cryo energy was done at the discretion of the electrophysiologist and not 
randomized. The groups were balanced to achieve the same number of men and women in 
each group. Patients with long-standing persistent AF were all treated with RF energy (Figure 
II). 
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Figure II.  Overview of randomization in Study IV 
                                  Group C                                                                                Group A 
 
The control group (C) was offered standard treatment and received analgesic and sedatives on request. The active group (A) 
had a premedication 30 min before the ablation and thereafter according to a predetermined protocol.  
 
4 DATA ANALYSIS 
Table V. Overview over statistical analyses used in the thesis 
Function Statistical method Study I Study II  Study III Study IV 
Summary and descriptions of 
observations division 
Descriptive statistics, mean 
standard deviation, or 
number and percentage 
√ √ √ √ 
Comparison of nominal data Fisher’s exact test √ √ √ √ 
 
Analyse of differences between   
two groups 
Unpaired t-test,   
(Student’s t-test, 
parametric test) 
 
√ 
 
√ 
 
√ 
 
√ 
 
Analysis of survival and the effect 
on explaining variables 
 
Cox regression 
  
√ 
 
Analysis of correlations between 
two or more variables (non-
parametric) 
Spearman’s correlation 
coefficient 
 
 
√ √ 
 
√ 
Linear regression analysis     √ 
A p-value of <0.05 was considered significant. The statistical analyses were conducted using IBM SPSS statistics 22 and 24 
for Windows (SPSS, Inc., Chicago IL) and R version 3.1.1. R Core Team (2014). R: A language and environment for statistical 
computing. R Foundation for Statistical Computing Vienna, Austria. 
  
Standard treatment; 
morphine and diazepam 
(n=40) 
20 men
10 RF
10 Cryo
20 women
10 RF
10 Cryo
Active treatment;
alfentanil. Premedication, 
mix midazolam (n=40) 
20 men
10 RF
10 Cryo
20 women
10 RF
10 Cryo
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5 ETHICAL CONSIDERATIONS 
The studies in this thesis followed the ethical principles outlined in the declaration of Helsinki 
for medical research on human subjects (104). All participants gave their written informed 
consent (Study I, II, and V) apart from Study III where only the patients alive at the follow-up 
could provide their consent. Considerations were taken concerning the deceased patients and 
it was judged that no harmful effect would be caused by including their data in the study. 
Permission to perform research in the clinical setting was obtained from the head of the 
clinic. The studies were also approved by the Regional Institutional Ethics Committee at the 
Karolinska Institute: Study I and II Dnr, 2011/1903-32/2; Study III 2010/914-31/1, 
2012/1390-32; and Study IV Dnr. 2006/632-31, EU-nr 2006-004415-22. 
The research in this thesis also conforms to the ethical principles for nursing research 
recommended by the Northern Nurses’ Federation. These principles include autonomy, 
beneficence, non-maleficence, and justice (105). 
The principle Autonomy:  With respect for the participant’s autonomy and integrity, all 
patients were able to decide whether they wanted to participate in the studies after receiving 
written and verbal information about the studies. Participation was entirely voluntary, and all 
patients received information about the right to withdraw from the research project without 
this decision affecting their continued care. All data were handled in a way to ensure 
confidentiality.  
The principle of beneficence: The patients included in the four studies did not benefit from 
participating, although the results may eventually improve treatment of arrhythmias and 
improve equality between the sexes in health care, referral, choice of pacemaker system, and 
analgesia during ablation procedures.  
 The principle of non-maleficence: We did not recognize any negative consequences of 
participating in the studies and did not find any risks that could harm the patients. 
The principle of justice: All eligible patients in Study I, II, and IV had the same chance to 
participate and were asked to participate. The aim was an equal number of the sexes in the 
studies to secure adequate comparison. Consequently, this strategy increased the inclusion 
period since fewer women than men are referred for ablation of AF. 
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6 RESULTS 
6.1 STUDY I 
Study I included 214 (109 women) referred for ablation due to PSVT: 43% were referred for 
ablation at first consultation, 83% were referred by specialists working in hospitals, and 4% 
were referred by their general practitioner. ECG-documented tachycardia was available in 
78% of the women and in 90% of the men (p = .03). Compared to men, women had a 
longer history of symptomatic arrhythmia before ablation. 
More women than men stated they were not taken seriously when they expressed concern 
about their tachycardia symptoms (17% vs.7%, p = .03). From the patient’s perspective, 
physicians more often incorrectly interpreted women’s symptoms as anxiety, stress, panic 
attacks, or depression, delaying referral for ablation. 
There were minor differences between the sexes in HRQOL and functional impairment at 
baseline, but women had more symptoms and scored higher on both scales of the SCL. At 
six months, women were still more symptomatic than men and their HRQOL improved 
less. There were no socioeconomic differences between men and women regarding level of 
education, income, or comorbidities. 
 
6.2 STUDY II 
A total of 242 (121 women) patients referred for PVI were studied – 74% with paroxysmal 
and 26% with persistent AF. There were no differences between the sexes with respect to 
proportion of paroxysmal/persistent AF, comorbidity, duration of AF, or acceptance of 
ablation when offered. Women were in mean three years older, had failed more drugs, and 
had less often undergone cardioversions before PVI. Women also had more symptoms, 
scored higher in both scales of the SCL, scored lower in all components in SF-36, and scored 
higher in five categories of the SIP at baseline. At six months, women were still more 
symptomatic and had improved less in HRQOL than men, although there were no differences 
in the SIP categories except for in home management. 
 
6.3 STUDY III 
This retrospective register study included 700 patients (359 women) who had undergone AVJ 
ablation between 1990 and December 2010. The women were older than the men at the time 
of ablation and more often had an indication of PAF and had a pacemaker programmed to 
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DDDR. HF was present in 44% of the men and in 28% of the women. In HF patients, CRT-
pacemaker was implanted before ablation in 42% of the men and in 18% of the women. 
Women less often than men received ICD or CRT even when there was an indication 
present. Complications in form of perforation or infection of the pacemaker or ICD system 
were seen in 6% of the men and 3% of the women. EF decreased slightly in the whole study 
group with no differences between the sexes. In addition, there were no differences in the 
RV-pacing group or the CRT group even though the CRT group was too small to show any 
significant difference between CRT and conventional pacing regarding impact on EF.  
 
During the follow-up, 366 patients died after a mean of 78 ±26 months. Time to death after 
the ablation was shorter for patients ablated after 2001 compared to the group ablated 
before 2001. The patients ablated after 2001were older, had more co-morbidities, and had 
their pacemaker programmed to VVIR more often, indicating a more advanced disease, 
which may explain the increased mortality in this group (Figure III.) There were no 
differences between the sexes regarding primary cause of death. Cardiovascular mortality 
was the most common cause of death (26%), coronary diseases 13%, HF 6%, stroke 3%, 
and AF 3%. The main factor influencing survival was age at the time of ablation. 
 
Figure III. 
 
At the beginning of the follow-up, mainly VVIR systems were implanted. Between 1993 and 2005, the use of DDDR 
increased to equal of the use of VVIR systems. After 2005, the use of VVIR system increased again, indicating a sicker 
population. 
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6.4 STUDY IV 
In Study IV, a total of 80 (40 women) patients were included. The results show that almost all 
patients (91%) experienced pain during the PVI. Premedication and regular administration of 
analgesic resulted in fewer drug administration occasions and less pain measured as numeric 
rating scale (NRS). Women experienced more pain than men regardless of energy type. Cryo 
energy ablation was experienced less painful compared with RF energy. There were no 
differences between men and women in the location of pain. The chest was the most 
frequently reported region during RF energy ablation. Half of the patients in the cryo energy 
group experienced pain located on the forehead. A side effect of PVI due to the long 
procedure time was back pain (not related to ablation application per se), which was reported 
by 31 of the 80 patients. Furthermore, 14 of the patients reported that they had pain in their 
limbs due to the long procedure time and the post ablation period when they were confined to 
bed (Figure IV). Procedure time was similar for the group receiving active treatment 
compared with that for the group receiving standard treatment.  
Most frequently used sensory description of the pain was burning, pressing, or stabbing. The 
affective description of the pain was that it felt troublesome and irritating. Four patients also 
described their pain as torturing. All these patients were in the RF energy group and three of 
them had received the more active pain strategy. 
 
Figure IV. Localization of pain in the different study groups 
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7 GENERAL DISCUSSION 
7.1 PRINICIPAL OBSERVATIONS 
The following list are our principal observations:  
• Women’s symptoms during PSVT were more often incorrectly interpreted as 
anxiety, stress, panic attacks, or depression compared to men. 
• Gender discrepany found in the referral for curative PSVT ablation was not seen in 
AF patients referred for PVI. 
• HRQOL improved more for men than for women after PVI. 
• Sex bias was evident in the choice of pacing system before AVJ ablation. 
• EF decreased slightly in the whole cohort after AVJ ablation. 
• More active supply of analgesic and sedative drugs should be used to reduce pain and 
discomfort during the PVI procedure. 
The following section discusses these main observations. More detailed discussion regarding 
methodology are given in each paper. 
 
7.2 COMPARISON WITH OTHER STUDIES 
7.2.1 Referral 
The results of Study I indicate that symptoms due to PSVT often are incorrectly diagnosed as 
panic attacks, stress, anxiety, or depression. These misdiagnoses delay referral for ablation, 
especially for women. Similar results have been described in other studies (68, 72). PSVT 
and panic disorder is known to coexist, and the symptoms are much alike (68, 106). 
Palpitations during PSVT are commonly associated with anxiety and panic disorder are 
characterized by sudden attacks of intense fear, palpitations, and tachycardia and may 
therefore be misdiagnosed.  
Other causes for referral delay may be a wish to record the tachycardia on ECG as 
documentation, but many times the arrhythmia ceased before it could be verified. In Study I, 
78% of the women and 90% of the men had a documented episode of arrhythmia when they 
were referred for ablation. These results are in accordance with earlier reports (107, 108). 
Lessmeier et al. (1997) found that inappropriate rhythm detection techniques (Holter instead 
of event monitoring) delay the diagnosis of PSVT (72).  The ambition to document the 
tachycardia on ECG is contrary to the ACC/AHAA/ESC guidelines from 2003 (the most 
 26 
 
recent guidelines during the period of the present study). The guidelines state that if 
symptoms and clinical history indicate that an arrhythmia is paroxysmal and resting 12-lead 
ECG gives no clue for the arrhythmia mechanism, further diagnostic tests for 
documentation may not be necessary before referral for an invasive electrophysiological 
study and/or catheter ablation (66). It is reasonable to presume that this ambition to 
document a tachycardia episode on ECG results in an unnecessary delay for both men and 
women. 
Study II found no differences between the sexes regarding time in AF before referral for PVI. 
In addition, Study II found that the women had not more comorbidities than the men even if 
they were older at the time of the ablation. This indicates a more aggressive treatment 
strategy than reported in other studies. These studies found that women were older and had 
more comorbidities before PVI and were referred later than men (60, 61, 109, 110).  
 
7.2.2 Gender discrepancies in the choice of pacemaker system  
In Study III, a long-term follow-up study (20 years) of patients undergoing AVJ ablation, we 
found gender discrepancies in the choice of pacemaker system before the ablation. Women 
with HF less often received CRT or ICD even when indication was present. Similar disparity 
has earlier been reported by Alaeddini et al. (111). Women had consistently higher rates of 
hospital admission for HF, but CRT-P and CRT-D were used less frequently in women than 
in men (111). The reason for this gender disparity in using CRT devices are unknown. Linde 
et al. also reported in a large retrospective register study that the proportion of CRT was 
lower in women, but CRT was equally underused in both sexes (112). 
7.2.3 Decreased EF after AVJ ablation 
We found a slightly decreased EF in the whole cohort after AVJ ablation despite the use of 
CRT. Similar results have been reported predominantly in patients with previous HF (113).  
One reason may be that the RV pacing caused left ventricular (LV) dyssynchrony, and thus 
decreased EF. Similar results have been reported in several studies before (114-117). 
Brignole et al. compared RV, LV, and BiV pacing and found only modest or no favourable 
effect with LV and BiV pacing sites (118).  
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7.2.4 Analgesic and sedation to reduce pain during PVI 
The PVI procedure can be long lasting and relatively painful (84). Almost all patients in our 
study experienced less pain during PVI with cryo technique than with RF energy. This result 
agrees with other studies (82, 83, 119). Moreover, the PVI procedure may also cause 
discomfort and anxiety (84). Our result in Study IV shows that the pain was not solely caused 
by the ablation; 39% of our patients experienced backpain and pain from the limbs due to the 
long period they were confined to bed during and after the procedure.   
We used intravenous sedation so the patients, despite their depressed level of consciousness, 
could respond to verbal commands and physical stimulation (120). General sedation has the 
disadvantages that it requires the presence of full anaesthesia support, which can cause 
scheduling difficulties. A third alternative is to use deep sedation with the goal to keep the 
patient in deep sedation while maintaining spontaneous ventilation throughout the procedure. 
Kottkamp et al. showed that deep sedation during ablation can be performed in environments 
with experienced electrophysiologists and nurses specially trained and with long experience 
with sedation and analgesia (121). This is not always achievable and cannot be generally used 
in EP labs without this special competence.  
 
7.2.5 HRQOL, symptoms and functional impairment 
In Study I and II, HRQOL was impaired in the patients before the cardiac ablation but 
improved after the procedure. However, the HRQOL improved more for men than for 
women. Women also were more symptomatic and reported more functional impairment than 
men. They were also more symptomatic after PSVT as well as after PVI ablation than the 
men. It is unclear why this is the case. If the symptoms are caused by supraventricular 
premature beats, the clinical experience is that symptomatic premature beats diminish 
gradually during the first six months after ablation. However, since women are more 
symptomatic to tachycardia per se, it is reasonable to assume that they also experience more 
symptoms due to premature beats after ablation (70, 107). In Study I, we compared women 
50 years and younger with those older than 50 years just to clarify that the symptoms were 
not post-menopausal symptoms. We found no differences regarding symptoms after 
ablation in the two groups. 
Individuals who experience severe symptoms and functional impairment and a low HRQOL 
caused by arrhythmia sometimes find the simplest daily activities difficult. Even if they do 
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not have symptoms between the attacks, earlier studies show that the memory of arrhythmia 
attacks may have negative impact on activities and ambitions (85). Concerns about whether 
an arrhythmia will start can affect and limit the individual in several ways, for example, her 
tendency to make longer trips. Some choose to travel only within the country and to places 
where hospital access is easy to find (Figure V). Bohnen et al. showed that the quality of life 
of close relatives was also influenced negatively because of the uncertainty and anxiety for 
his/her partner (122) . Similar results were presented in a Swedish study by Dalteg et al. 
(123).  
                  Figure V. Description of the effect of impaired HRQOL in arrhythmia patients  
  
 
Physical impairment: symptoms such as fatigue, palpitations, irregular heart beats, 
and dizziness. 
Social impairment: unwillingness to travel, go to the cinema, and visit friends because 
of the fear of an arrhythmia episode. 
Psycological impairment: stress, anxiety, and depression.  
 
 
Evaluation of arrhythmia symptoms can be difficult. Many patients have underlying heart 
diseases that can produce symptoms such as weakness, light headedness, and dyspnoea, 
symptoms that are also very common during arrhythmia. Moreover, patients with chronic 
diseases, especially women, feel that they are not being listened to and taken seriously when 
seeking medical care (108). Patients with PSVT often have a long history of numerous visits 
to doctors and/or hospital emergency departments. In many cases, the arrhythmia had expired 
before it could be verified by ECG. This may result in avoiding seeking help when 
experiencing new tachycardia episodes. Wood et al. describes this situation as follows: 
Physical
impairment
Social 
impairment
Psychological
impairment
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An ambiguity when and where the next arrhythmia episode will start and/or 
how long the episode will last. A need to "cover up" and deal with the 
symptoms so that everything seems normal in front of relatives or colleagues 
(108). 
This reaction might lead to self-treatment:  
 
To self-try to find causal factors to prevent new episodes to occur and to 
experiment and try different strategies to shorten or get a current episode to a 
halt e.g. with different types of breathing exercises, yoga, straining or dip your 
face in cold water (108). 
 
7.3 POTENTIAL MECHANISM 
7.3.1 Sex differences in studies 
Differences in biology between women and men have been described in the report 
“Exploring the Biological contributions to Human Health” (2001) by The Institute of 
Medicine in the United States. They state when it comes to the sciences of medicine and 
clinical practice, sex is an important issue and must be taken into consideration (124). 
Although women traditionally been underrepresented in trials, results have been extrapolated 
to the female population that assume identical results in men and women. If studies only 
include men, they should explain why and how this introduces limits to the generalizability of 
the study (76).  
Men more often than women are referred for cardiac ablation due to AF. This leads to an 
underrepresentation of women in cardiac ablation studies and might lead to insufficient 
knowledge of treatment outcome in women and lack of sex-specific recommendations and 
under-utilization of existing guideline-based therapies for women (125). In the German 
ablation registry, only 33% of the cohort were women (126). This is in accordance with data 
from the Swedish ablation registry and our clinical experience.  
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7.4 STRENGHT AND LIMITATION 
Study I and II were based on questionnaires. The response rate was 56% in Study I and 65% 
in Study II. There is some uncertainty performing studies with only questionnaires. How 
honest are the patients? Have the patients answered the questionnaires themselves? Are there 
too many questions for patients to answer? Did the patients who denied participation have 
more or fewer symptoms than those who chose to participate? We assume that the 
participating patients are representative. 
Study III was based on data from the hospital’s ablation register, medical records, and data 
from the National Patient Registry (NPR) kept by the National Board of Health and 
Welfare. The sources of register data are both a strength and a weakness. Sweden is unique 
because the social security number (a personal identification number assigned to all legal 
residents and citizens) gives researchers the ability to freely retrieve data from the NPR. 
This is an advantage in comparison with other countries when retrospectively studying 
morbidity, mortality, and causes of death. Another advantage of this type of study 
compared to randomized studies is that register studies capture data from real life practice 
in larger and unselected cohorts.  
Although register studies are inexpensive, and cost effective, they have limitations which is 
a weakness. The duration of specific diseases or diagnoses are often uncertain. Diagnoses 
are usually attached to patients their entire lives. Hence, it is not always possible to 
determine whether the reason for a patient’s visit to an out-patient clinic is, for example, HF 
or some other diagnosis. Another limitation is that recorded data are not always complete 
and may in some instances be incorrect. Over the years, the routines for medical records 
and data recorded in registries have changed as has what is considered a normal range for 
various lab tests, including echocardiography. Therefore, when comparing data from 1990 
with data from 2010, the conclusions should be made with some caution. 
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8 CONCLUSIONS OF THE THESIS 
• Women with PSVT are referred for curative ablation later than men despite more 
symptoms. 
 
• Symptoms due to PSVT are often incorrectly diagnosed as panic attacks, stress, 
anxiety, or depression, misdiagnoses that delay referral for ablation, especially for 
women. 
 
• Women with AF are more symptomatic and report worse HRQOL and functional 
impairment than men, but there are no differences in the duration of the AF before the 
PVI or when referred for ablation when indicated.  
 
• Women are still more symptomatic after both PSVT and PVI ablation than men. 
 
• Indication, choice of pacing system, and morbidity differed between the sexes in 
patients with AF treated with AVJ ablation. 
 
• EF decreased slightly in the whole study cohort after AVJ ablation. 
 
• There were no sex differences regarding survival or primary cause of  death after 
AVJ ablation. The main factor influencing survival was age at the time of ablation. 
 
• Women less often than men received treatment with ICD and/or CRT when 
indication was present before AVJ ablation.  
 
• An active regular supply of analgesic and sedative drugs reduce pain and discomfort 
during PVI in both sexes. 
 
• Women experience more pain than men during PVI.  
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9 CLINICAL IMPLICATIONS TO ACHIEVE A MORE EQUAL 
HEALTH CARE FOR THE SEXES 
 
1)  It is necessary to include and describe results for both sexes in clinical and 
cardiovascular studies. We found several differences between the sexes and this 
knowledge may help us to tailor a good health care in the daily work with arrhythmia 
patients. 
 
2) There seems to be major differences in how physicians interpret tachycardia 
symptoms in men and women leading to differences in referral patterns. Therefore, it 
is of great importance to increase and improve the information to achieve equality 
between the sexes in treatment and referral according to existing guidelines with 
respect to the arrhythmia disease. 
 
3) Our results indicate a need for a systematic approach for implementation of guidelines 
and for person-centred health care for arrhythmia patients (127, 128). A tailored 
integrated education program involving the patient might solve some issues. To 
correct misperceptions of the arrhythmia and treatment, eduation programs addressing 
the HRQOL should be developed within a multidisciplinary team of allied health 
professionals (129). Person-centred care integrates education and shared decision 
making with the patients. This may be of particular value in the management of 
patients with arrhythmia (130). The need to prevent and treat arrhythmia patients 
effectively where women’s and and men’s needs are evaluated is necessary to avoid 
increasing health costs and to increase the benefits for individual patients.  
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10 SVENSK SAMMANFATTNING 
Bakgrund Kvinnor och män skiljer sig åt vad gäller prevalens av förmaksarytmier. Tidigare 
studier har visat det också finns könsskillnader i remittering, handläggning, symtombörda, 
hälsorelaterad livskvalitet (HRQOL), funktionsnedsättning, riskfaktorer och resultat av olika 
behandlingsalternativ vid paroxsysmal supraventrikulär takykardi (PSVT) och 
förmaksflimmer. 
Syfte Det övergripande syftet med denna avhandling har varit att studera genus-och 
könsskillnader i remittering, behandling, symtom, HRQOL och funktionsnedsättning, 
riskfaktorer och resultat hos patienter som genomgår ablationsbehandling av PSVT eller 
förmaksflimmer.   
Metod Avhandlingen bygger på fyra studier. Studie I och II är prospektiva 
observationsstudier baserade på enkäter och medicinska journaler, före samt sex månader 
efter ablationsbehandling. I Studie I ingick 214 (109 kvinnor) patienter remitterade för 
ablation av PSVT. I Studie II ingick 242 (121 kvinnor) patienter med förmaksflimmer 
remitterade för lungvensisolering. Följande enkäter användes i Studie I och II: Symtom 
Checklista: frekvens och svårighetsgrad, SF-36 samt Funktionsschema. Remitteringsgång, 
socioekonomiska data samt symtomduration utvärderades med ett separat frågeformulär. I 
studie III ingick 700 patienter (359 kvinnor) som genomgått His-ablation mellan åren 1990 
till 2010. Studien baserades på registerdata insamlade från patientjournaler, svenska ICD-och 
pacemakerregistret och från det nationella patient-och dödsregistret som tillhandahålls av 
Socialstyrelsen. I Studie IV randomiserades 80 (40 kvinnor) patienter antingen till en aktiv 
eller standardiserad smärtbehandling under lungvensisoleringen med kryo- eller 
radiofrekvensenergi. Utvärderingen av de två behandlingsstrategierna utvärderades med en 
enkät baserad på Pain-O-Metern.  
Resultat Kvinnorna med PSVT i Studie I upplevde mer symtom, men remitterades för 
ablationsbehandling i genomsnitt sex år senare än männen. Dessutom rapporterade kvinnorna 
att de oftare inte kände sig trodda när de sökte hjälp och beskrev sina arytmisymtom. De fick 
oftare diagnoser såsom stress och ångest. I studie II fanns inte samma könsskillnad hos 
förmaksflimmerpatienterna gällande remitteringen, men kvinnorna var mer symtomatiska, 
skattade en lägre HRQOL och en större funktionsnedsättning än männen. Dessutom hade 
kvinnorna oftare fått pröva fler läkemedel och blev mindre ofta än männen remitterade för 
elkonvertering före lungvensisoleringen. I studie III hade fler män än kvinnor en diagnos med 
hjärtsvikt före His-ablation. När indikationen fanns erhöll kvinnorna mindre ofta än männen 
mer avancerade pacemakersystem såsom ICD eller CRT-system före His-ablationen. Det 
förelåg ingen skillnad mellan könen när det gällde den primära dödsorsaken efter His-
ablationen. Den vanligaste dödsorsaken för bägge könen var hjärta-och kärlsjukdom och den 
viktigaste parametern som påverkade överlevnaden var ålder vid tidpunkten för His-
ablationen. I studie IV upplevde 90 % av patienterna smärta under lungvensisoleringen. 
Premedicinering och regelbunden administrering av smärtstillande läkemedel resulterade i 
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mindre smärta och färre läkemedels administrationstillfällen. Kvinnorna upplevde mer smärta 
än männen oavsett energityp, kryo- eller radiofrekvensenergi.  
Slutsatser Alla fyra studier visade genus och/eller könsskillnader i antingen remittering, 
sjuklighet, symptom, HRQOL, funktionsnedsättning eller resultat av behandling. Kvinnorna 
med PSVT och förmaksflimmer behandlades mer konservativt än männen. Kvinnorna med 
PSVT remitterades för botande ablationsbehandling flera år senare än männen, trots mer 
symtom. Arytmisymtomen hos kvinnorna blev oftare felaktigt diagnostiserade såsom 
panikattack, stress, ångest, eller depression. Kvinnorna med förmaksflimmer upplevde mer 
symtom, skattade en lägre HRQOL och en större funktionsnedsättning före 
lungvensisoleringen än männen. Trots detta, blev de mer sällan remitterade för elkonvertering 
före lungvensisoleringen. Kvinnorna erhöll mindre ofta de mer avancerade 
pacemakersystemen såsom CRT-eller ICD även när indikationen fanns före Hisablationen. 
Det fanns inga könsskillnader när det gäller överlevnad eller primär dödsorsak efter His-
ablationen. Den viktigaste faktorn som påverkade överlevnaden var ålder vid tidpunkten för 
ablation. Kvinnorna upplevde mer smärta än männen under lungvensisoleringen, men en 
aktiv regelbunden tillförsel av smärtstillande och lugnande läkemedel minskade smärtan och 
obehaget under ablationen för båda könen. 
 
 
 
 
  
 35 
 
11  ACKNOWLEDGEMENTS 
I would like to express my sincere gratitude to all of you who have supported and believed in 
me during these years and my doctoral studies and made this thesis possible.  
In particular, I would like to thank the following persons. 
 
Per Insulander, my principal supervisor: Thank you for all support and encouragement and 
your patience with me when my patience was long gone. Thank you for answering all the 
questions I had along the way and your valuable guidance in research that you always found 
time to share with me. Without your support from the beginning to the end, this thesis would 
never have been written. 
 
Marie Iwarzon, my co-supervisor, thank you for all your support and help and all your deep 
knowledge of questionnaires and health-related quality of life. Thank you!  
 
Fredrik Gadler, my co-supervisor and boss. Thank you for your positive support and for 
giving me the opportunity and time to perform my research despite all staffing problems.  
 
Michael Melin, my mentor. Thank you for interest in my work and wellbeing. One day we 
will have that lunch. 
 
Mats Jensen-Urstad, one of the first who introduced me to research, thank you for providing 
me with time to perform it and giving me lots of good advice along the way. 
 
Eva Hägglund, thank you for your encouragement and for all inspiring discussion about life, 
statistical issues, and the future and for just being there when I needed you. It has been great 
to have you by my side along this journey. 
Nicola Drca, for all the laughs and for just being such a jolly good fellow. Life is so much 
easier when people like you are around. 
Cecilia Linde, former head of the Department of Cardiology, Karolinska University Hospital 
for promoting and showing interest in my research. 
Fanny Edfeldt, Hanna Carnlöf, and Gunilla Förstedt, thanks for all hours you helped me with 
the data logging and distribution of all mail. 
Minna Bergman, for verbatim type the interviews in the that were used in Study I and II.   
 36 
 
Andreas Vaitsis, thank you for your valuable help with the statistic course. I would never 
have managed to complete the course without you. 
The staff at the EP lab, nurses and doctors for excellent assistance with Study IV.  
Christer Wredlert, for always helping me out when I have computer problems. Often with just 
one finger touch, and for teaching me to say NO and NOW! 
All my dear friends at the echo laboratory, Aristomenis Manouras, Christina Oliveira Da 
Silva, Linn Vang and Elif Günyeli for your extraordinaire competence and for always finding 
your time to help me with my study patients. 
My colleagues Karin Hellkvist and Terhi Wallebom for your support, positive 
encouragement and giving me time to perform my research when I most needed it. 
Irene Saviaro, do not ever stop to be my personal helpdesk! Your help through the years with 
data programs and the coffee machine have been invaluable. 
Anita Furö and Monica Broberg, thank you for your support with rooms and your interest in 
my research and wellbeing.  
All my friends and colleagues at the Heart and Vascular Theme –none mentioned, none 
forgotten. 
My physiotherapist, Anders Lånström, for keeping me in shape and on my feet during the 
two last years.   
 
My late father and mother who never stopped believing in me. You would have been so 
proud. I miss you. 
 
To my family – my husband, Lars, children Calle, Anders and Hanna, grandchildren Victor, 
Anton, Lova and William, and daughters-in-law Amanda and Isabelle – you are the joy and 
help me keep the right balance in my life. 
 
I will also express my gratitude to the funders. This research work was supported by grants 
from the Women and Health Foundation, 1.6 Million Club, The Swedish Heart and Lung 
Association, the Department of Cardiology, Karolinska University Hospital, and allied Health 
Professions within Cardiology. 
 
Finally, thanks to all the patients who took their time to answer the questionnaires. 
 
 
 37 
 
12 APPENDIX 
 
Appendix 1) Intervjuguide till studie I och II 
Appendix 2) Avslutande frågor angående remittering Studie 1 och II 
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Appendix 1.  Intervjuguide till studie I och II 
Presentation av mig, syftet med intervjun, arbetar du el studerar? 
Kan du berätta/ beskriva om första gången du kände att något var annorlunda? 
Sökte du hjälp vid det tillfället? 
Vilken sorts hjälp och var?  
Har du väntat länge på att söka hjälp? Hur länge då? 
Hur blev du bemött/ betrodd? 
Vad fick du för besked? 
Fick du några råd om hur du vid ev. återkommande besvär skulle agera? 
Hur/vad kände du då? 
När fick du din diagnos? 
Vilken sorts information fick du om din hjärtsjukdom; skriftliga? Muntliga? 
Har du ätit några mediciner för att lindra dessa och i så fall vilka? 
När var första gången du blev informerad om att dina hjärtbesvär kunde botas? 
 Har du väntat länge på behandling? 
 Hur frekventa har dina hjärtbesvär varit? 
 Vilken behandling föreslogs? 
 Har du känt dig tveksam till denna behandling? 
 Har du och sökt information via internet? Anhöriga/närstående? Litteratur?    
 Hemsidor? Annat? 
Hur har dina hjärtbesvär påverkat ditt liv? 
 Begränsningar? Bilkörning, socialt umgänge familjen, semestrar? 
 Sjukskrivning/ Arbete %? Hur mkt? 
 Ångest? Oro? Annat? 
 Vilket stöd alt hjälp har du fått i samband med detta? 
Vilka besvär/symtom har du haft under hjärtklappningsattackerna? 
Därefter se: SCL saknar du något symtom? 
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Appendix 2 Avslutande frågor Studie I och II 
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